Table 1. Main characteristics of included studies.
| Author | Year | Country | Disease | Situation | Surgery | Radiotherapy | Experimental Group | Control Group | OS (HR and 95%CI) | PFS (HR and 95%CI) |
||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Size | Drugs | Size | Drugs* | |||||||||
| Solomon | 2013 | Cuba | HGG | -# | Biopsy/Resection | √ | 38 | E | 32 | A | 0.68 (0.42,1.11) | 0.75 (0.49,1.16) |
| Stupp | 2005 | Switzerland | GB | Newly | Biopsy/Resection | √ | 287 | B | 286 | A | 0.63 (0.52,0.75) | 0.54 (0.45,0.64) |
| van den Bent | 2006 | Netherland | AO/AOA | - | Biopsy/Resection | √ | 185 | C | 183 | A | 0.85 (0.65,1.11) | 0.68 (0.53,0.87) |
| Shaw | 2012 | USA | LGG | - | Biopsy/Resection | √ | 125 | C | 126 | A | 0.72 (0.47,1.10) | 0.60 (0.41,0.86) |
| Chinot | 2014 | France | GB | Newly | Biopsy/Resection | √ | 458 | D | 463 | B | 0.88 (0.76,1.02) | 0.64 (0.55,0.74) |
| Tham | 2013 | Australia | AO/AOA | - | Biopsy/Resection | √ | 36 | B | 26 | A | 1.03 (0.50,2.11) | 1.29 (0.71,2.33) |
| Stupp | 2014 | Switzerland | GB | Newly | Biopsy/Resection | √ | 272 | F | 273 | B | 1.02 (0.81,1.29) | 0.93 (0.76,1.13) |
| Kim | 2011 | Korea | GB | Newly | Biopsy/Resection | √ | 40 | G | 42 | B | 0.52 (0.24,1.12) | 0.89 (0.49,1.62) |
| Hildebrand | 2008 | Belgium | AO/AOA | Newly | Biopsy/Resection | √ | 94 | H | 99 | A | 0.77 (0.56,1.06) | 0.75 (0.57,0.99) |
| Levin | 2000 | USA | GBM | - | Biopsy/Resection | √ | 134 | I | 138 | C | 1.00 (0.90,1.10) | 1.00 (0.90,1.10) |
| Muni | 2010 | Italy | GB | Newly | Biopsy/Resection | √ | 22 | B | 23 | A | 0.50 (0.26,0.99) | 0.52 (0.29,0.93) |
| Kocher | 2008 | Germany | GB | - | Resection | √ | 29 | B | 33 | A | 0.84 (0.44,1.62) | 0.91 (0.49,1.67) |
| Nabors | 2015 | USA | GB | Newly | Biopsy/Resection | √ | 88 | F | 89 | B | 0.69 (0.48,0.97) | 0.82 (0.60,1.13) |
| Combs | 2008 | Germany | AO/AOA | - | Biopsy/Resection | √ | 20 | B | 40 | A | 1.51 (0.76,3.02) | 1.86 (0.97,3.57) |
HGG: High Grade Glioma (include GBM+AO/AOA); GB: Glioblastoma; AO/AOA: Anaplastic Oligodendroglioma/Oligoastrocytomas; LGG: Low Grade Glioma; GBM: Glioblastoma Multiforme; HR: Hazard Ratio; OS, Overall Survival; PFS, Progression-free Survival; -, none reported.
*
A: Placebo; B: TMZ; C: PCV; D: BEV+TMZ; E: Nimotuzumab; F: Cilengitide+TMZ; G: TMZ+ACNU+CDDP; H: DBD+BCNU; I: DMFO+PCV; TMZ: Temozolomide; PCV: Procarbazine, Lomustine and Vincristine; BEV: Bevacizumab; ACNU: Nimustine; CDDP: Cisplatin; DBD: Dibromodulcitol; BCNU: Carmustine; DMFO: Eflornithine;